FDA approves Jentadueto™ tablets for the treatment of adult patients with type 2 diabetes
PRESS RELEASE
New treatment combines DPP-4 inhibitor, linagliptin (the active ingredient in Tradjenta™ (linagliptin) tablets), and metformin in a single tablet, taken twice-daily, to lower blood sugar in adults with type 2 diabetes.
Ridgefield, Conn., and Indianapolis, Jan. 30, 2012– Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) has approved Jentadueto™ (linagliptin/metformin hydrochloride) tablets, a new tablet combining the dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, and metformin. JENTADUETO provides a new, single-tablet treatment option, taken twice-daily, for patients who need to control their blood sugar. Linagliptin (5 mg, once-daily) is marketed in the U.S. as Tradjenta™ (linagliptin) tablets.
JENTADUETO is a prescription medication used along with diet and exercise to improve glycemic control in adults with type 2 diabetes when treatment with both linagliptin and metformin is appropriate. At the maximum dose, JENTADUETO demonstrated placebo-corrected reductions in hemoglobin A1C (HbA1C or A1C) levels of up to 1.7 percent (+0.1 percent for placebo and -1.6 percent for JENTADUETO). A1C is measured in people with diabetes to provide an index of blood sugar control for the previous two to three months. JENTADUETO did not cause any meaningful change in body weight. JENTADUETO can be used alone or in combination with a sulfonylurea, a commonly prescribed medication for type 2 diabetes. JENTADUETO is not for the treatment of type 1 diabetes or diabetic ketoacidosis (increased ketones in the blood or urine). It has not been studied in combination with insulin. The JENTADUETO label contains a boxed warning for the risk of lactic acidosis, a serious metabolic complication that can occur due to metformin accumulation during treatment with JENTADUETO.
Click here for full prescribing information.
Tags: 2, medication, oral, treatment
Replies to This Discussion
-
Permalink Reply by gphx on -
At a starting A1C of say, 8, a 1.7% improvement drops it down .136 points to 7.864. Such a minor improvement hardly seems worth the expense or risk of lactic acidosis.
One could probably get as much improvement out of a dozen jumping jacks or walking a single block each day.
-
Permalink Reply by David Contreras on
-
so is anyone taking this new drug?
my Dr. recently prescribed this to me but as always, I am leery.
-
Permalink Reply by Peetie on -
Oh great! Yet another drug to use. Every time I see a drug discredited, like the Actos in the above post, I think "Phew! Another one bites the dust! Maybe now T2s will get decent treatment." .... and...here it is ... another drug to test out on unwilling lab rats!
I read on here all the time that the T2 drugs are useless for LADA and T1s.... What is not mentioned is the fact that they rarely work for T2s either.
A doctor on this site once posted..."don't be the first to try a new drug". Really!...enough is enough.
-
Permalink Reply by PatientX on -
Yep. When januvia first came out I was put on it and I felt so bad. Every time I hear of a new drug I think there goes my stomach. I will stick with metformin until I need insulin.
-
Permalink Reply by Anita Logan on -
I feel the same way: metformin until I need insulin
Advertisement
REsources
Groups
From the Diabetes Hands Foundation blog...
Congratulations Diabetes Advocates Scholarship Recipients!
The Diabetes Hands Foundation and Diabetes Advocates Program is proud to announce and congratulate the members of DA who were granted scholarships to attend diabetes conferences in 2013! Thanks to a generous grant from Novo Nordisk, in 2013 we were …Continue Reading
La Familia de EsTuDiabetes Sigue Creciendo
El Centro Nacional de Prevención de Enfermedades Crónicas y Promoción de la Salud en el Estados Unidos encontró que a partir de 2002-2009, el 11,8% de los hispanos mayores de 20 años, que viven en los EU, viven con diabetes …Continue Reading
TuDiabetes Team
DHF STAFF
 Manny Hernandez(Co-Founder, Editor, has LADA)
|
DHF VOLUNTEERS
Lead Administrator
 Bradford (has type 1) |
Administrators
 Lorraine (mother of type 1) |
 Marie B (has type 1) |
|
|
|
|
|
|
LIKE us on Facebook
Spread the word
This site complies with the HONcode standard for trustworthy health information: verify here.
© 2013 A community of people touched by diabetes, run by the Diabetes Hands Foundation.
